Skip to main content
NEUROTECH INTERNATIONAL LIMITED logo

NEUROTECH INTERNATIONAL LIMITED — Investor Relations & Filings

Ticker · NTI ISIN · AU000000NTI9 ASX Professional, scientific and technical activities
Open in API
Filings indexed 667 across all filing types
Latest filing 2023-09-17 Regulatory Filings
Country AU Australia
Listing ASX NTI

About NEUROTECH INTERNATIONAL LIMITED

https://neurotechinternational.com/

Neurotech International Limited is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for neurodevelopmental and neurological disorders. The company specializes in neuroprotective therapies, primarily targeting pediatric conditions with significant unmet medical needs, including Autism Spectrum Disorder (ASD), Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS), and Pediatric Acute-onset Neuropsychiatric Syndrome (PANS). Its lead drug candidate, NTI164, is a proprietary, broad-spectrum cannabinoid formulation derived from a unique cannabis strain. NTI164 is engineered to exert anti-inflammatory and neuroprotective effects by modulating neuroinflammatory pathways. The company conducts clinical trials to establish the safety and efficacy of its treatments, aiming to provide transformative behavioral and functional improvements for patients.

Recent filings

Filing Released Lang Actions
Secondary Trading Notice 1 page 96.4KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 18 September 2023. It is titled 'Secondary Trading Notice Pursuant to Section 708A(5)(e) of the Corporations Act' and discusses the issuance of ordinary fully paid shares without disclosure under Part 6D.2 of the Corporations Act. The content focuses on compliance with specific sections of the Corporations Act and provides no financial statements or detailed financial data. The document is short (2743 characters) and serves as a regulatory notice about share issuance and compliance rather than a full financial report or detailed capital update. It does not contain financial results or management discussion, nor is it a report publication announcement. Given the nature of the notice and its regulatory compliance focus, the best fitting category is Regulatory Filings (RNS).
2023-09-17 English
Appointment of Corporate Advisor 2 pages 96.0KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated 15 September 2023 regarding the appointment of a corporate advisor, Merchant Corporate Advisory Australia Pty Ltd, by Neurotech International Limited. It details the terms of the advisory mandate, including the issuance of options as consideration, subject to shareholder and ASX approval. The document does not contain financial statements, earnings data, or detailed report content. It is a corporate update about a financing-related advisory appointment and option issuance, not a full financial report or earnings release. Given the content focuses on corporate advisory appointment and related capital structure implications, it fits best under Capital/Financing Update (CAP). The document length is 4160 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, the classification is CAP with high confidence.
2023-09-14 English
Proposed issue of securities - NTI 7 pages 35.1KB
Capital/Financing Update Classification · 100% confidence The document is an announcement regarding a proposed issue of securities by Neurotech International Limited. It details the type of securities (unlisted options), the number of securities to be issued, the proposed issue date, conditions such as shareholder approval, and other specifics related to the placement or issue of new securities. There is no financial performance data, earnings information, or management discussion. The document is clearly an update on capital raising activities and changes in the company's capital structure. This fits the definition of a Capital/Financing Update (CAP). The document length is over 10,000 characters and contains detailed information about the proposed securities issue, not just a brief notice or a link to a report, so it is not a Report Publication Announcement (RPA) or Regulatory Filing (RNS).
2023-09-14 English
Clinician Briefing Presentation and Webcast 19 pages 2.2MB
Investor Presentation Classification · 95% confidence The document is an ASX announcement dated 15 September 2023 from Neurotech International Limited. It primarily contains an investor presentation and details about a clinical-stage biopharmaceutical company's research and clinical trials, including a webinar and Q&A session with a professor. The content is educational and promotional, focusing on clinical trials and company strategy rather than financial results or regulatory filings. The document is lengthy (15,000 characters) and includes detailed presentation slides and disclaimers. It is clearly an investor presentation intended to inform investors about the company's clinical pipeline, strategy, and research progress. There is no indication that this is an annual report, earnings release, or regulatory filing. The presence of a webinar and Q&A session further supports classification as an investor presentation. Therefore, the appropriate classification is Investor Presentation (IP).
2023-09-14 English
Proposed issue of securities - NTI 5 pages 27.2KB
Capital/Financing Update Classification · 95% confidence The document is an announcement from Neurotech International Limited regarding a proposed issue of securities, specifically a placement of 8,400,000 ordinary fully paid shares. It details the terms, conditions, and regulatory compliance related to the securities issuance, including references to ASX Listing Rules and the purpose of the issue (shares in lieu of cash fees for investor relations services). The document is structured as a formal announcement rather than a full financial report or detailed analysis. It does not contain financial statements or management discussion but focuses on the capital raising activity and issuance details. Therefore, it fits the category of Capital/Financing Update (CAP). The document length (6132 characters) supports it being a full announcement rather than a brief notice or a report publication announcement.
2023-09-14 English
Upcoming Clinician Briefing 3 pages 172.2KB
Investor Presentation Classification · 90% confidence The document is an ASX announcement dated 11 September 2023 from Neurotech International Limited. It invites shareholders to an upcoming investor webinar featuring a clinical update and Q&A session about a Phase I/II clinical trial for a neurological disorder treatment. The content focuses on providing information about the clinical trial, the company, and the webinar logistics. There are no financial statements, earnings data, or detailed financial analysis present. The document is an announcement of an investor presentation event rather than the presentation itself or a financial report. Therefore, the most appropriate classification is Investor Presentation (IP), as it is a detailed presentation for investors focusing on clinical and strategic updates.
2023-09-10 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.